The Brighterside of News on MSN21h
New nighttime nasal spray significantly alleviates sleep apneaA nighttime nasal spray may offer a new way to ease sleep apnea and lower blood pressure, according to Australian researchers ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...
The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and ...
Phenylephrine and pseudoephedrine are both active ingredients in nonprescription Sudafed products. However, phenylephrine has ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Last month, Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine ... made Spravato the first-ever standalone treatment for adults with treatment-resistant depression. Give your business an edge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback